Earnings Highlights

First Quarter Highlights

2023 Guidance³

Delivering Sustained Growth and Innovation

Key Regulatory and Clinical Milestones

Strong Financial Foundation

BMS remains committed to maintaining a strong investment grade credit rating and returning capital to shareholders.

Business Development

• In April, the company announced an agreement for a vector facility to further strengthen its cell therapy supply chain and expand manufacturing capacity. This will allow Bristol Myers Squibb to dual-source vector supply and transition to newer, higher efficiency manufacturing processes. The transaction is expected to close in the second half of 2023, subject to the fulfillment of applicable closing conditions.

Environmental, Social and Governance Highlights^§

As a leading biopharmaceutical company, we understand our responsibility extends well beyond the discovery, development, and delivery of innovative medicines. Our evolving Environmental, Social, and Governance (ESG) strategy builds on a legacy of comprehensive and global sustainability efforts. To learn more about our priorities and goals, please visit our latest ESG report.

Looking Ahead

_{¹ GAAP and non-GAAP EPS include the net impact of Acquired IPRD charges and licensing income of ($0.01) per share in the first quarter of 2023 compared to ($0.10) per share in the first quarter of 2022. Acquired IPRD refers to certain in-process research and development (“Acquired IPRD”) charges resulting from upfront or contingent milestone payments in connection with asset acquisitions or licensing of third-party intellectual property rights.}

_{² Non-GAAP EPS is not calculated in accordance with U.S. Generally Accepted Accounting Principles ("GAAP"). This non-GAAP measure excludes certain costs, expenses, gains and losses and other specified items. A reconciliation of GAAP to non-GAAP measures can be found on our website at bms.com. See, “Quarterly package of financial information” available on bms.com/investors for additional information on the limitations of non-GAAP financial measures and the list of specified items excluded from non-GAAP EPS.}

_{³ The 2023 financial guidance excludes the impact of any potential future strategic acquisitions and divestitures, any specified items that have not yet been identified and quantified and the impact of any future Acquired IPRD charges and licensing income. For more information, see our earnings release for the first quarter of 2023, available at bms.com/investors.}

_{⁴ Excludes the impact of foreign exchange ("Ex-FX"). We calculate foreign exchange impacts by converting our current-period local currency financial results using the prior period average currency rates and comparing these adjusted amounts to our current-period results. Ex-FX financial measures are not accounted for according to GAAP because they remove the effects of currency movements from GAAP results.} 

_{⁵ New Product Portfolio includes Reblozyl^® (luspatercept-aamt), Inrebic® (fedratinib), Onureg^® (azacitidine tablets), Zeposia^® (ozanimod), Breyanzi^® (lisocabtagene maraleucel), Abecma^® (idecabtagene vicleucel), Opdualag^TM (relatlimab plus nivolumab fixed-dose combination), Camzyos^®(mavacamten) and Sotyktu^TM (deucravacitinib).}

_{Materials on this infographic may contain information about the company’s future plans and prospects that constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed.}

_{Forward-looking statements contained in this document should be evaluated together with the many risks and uncertainties that affect Bristol Myers Squibb's business, particularly those identified in the cautionary statement and risk factors discussion in the company’s most recent annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. These documents are available from the Securities and Exchange Commission, the Bristol Myers Squibb website or from Bristol Myers Squibb Investor Relations. The forward-looking statements included in this document are made only as of the date of this document and except as otherwise required by applicable law, the company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise.}

_{^‡ Reblozyl is being developed and commercialized through a global collaboration with Merck following Merck’s acquisition of Acceleron Pharma, Inc. in November 2021.}

_{^† Includes $1.2 billion for dividends paid and $250 million for common stock repurchases.}

_{¶ U.S. FDA supplemental Biologics License Application filed jointly with 2seventy bio, Inc.}

_{^§For more information on our Governance profile, including Board composition and oversight of strategy and key enterprise risks, as well as the ESG goals and commitments, please see our 2023 Proxy Statement and our 2022 ESG Report to be published later this year.}

_{* Bristol Myers Squibb Foundation, an independent charitable organization.} 

_{© 2023 Bristol-Myers Squibb Company. All Rights Reserved.}